Related Experiment Video

Updated: May 6, 2026

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
07:20

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood

Published on: January 9, 2018

9.5K

Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts

Yasuo Hachiya1, Akinori Uruha, Emi Kasai-Yoshida

  • 1Department of Neuropediatrics, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo 183-0042, Japan.

Journal of Neuroimmunology
|November 5, 2013
PubMed

Insights

Rituximab treatment for anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis reduced B cells and plasmablasts. Increased plasmablasts may predict a poor prognosis, indicating a need for immunotherapy.

Area of Science:

  • Neuroimmunology
  • Immunotherapy research
  • B cell biology

Background:

  • Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder.
  • Rituximab is an immunotherapy targeting CD20-expressing B cells.
  • Understanding B cell dynamics is crucial for managing NMDAR encephalitis.

Observation:

  • Rituximab treatment was evaluated in a patient with recurrent anti-NMDAR encephalitis.
  • Multicolor flow cytometry analyzed peripheral blood mononuclear cells (PBMCs).
  • Changes in B cell subsets and plasmablast numbers were measured post-treatment.

Findings:

  • Rituximab effectively depleted CD20-positive naive and memory B cell subsets.
  • A reduction in CD20-negative plasmablasts was observed following rituximab therapy.
  • This suggests rituximab indirectly targets short-lived plasmablasts via CD20+ cell depletion.

Implications:

  • Plasmablast levels in PBMCs might serve as a predictive biomarker for unfavorable anti-NMDAR encephalitis prognosis.
  • Elevated plasmablasts could signal the need for initiating second-line immunotherapy.
  • This research informs treatment strategies and prognostic indicators for NMDAR encephalitis.
Keywords:
Anti-NMDAR encephalitisCentral nervous systemFlow cytometric analysisRituximab

More Related Videos

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

15.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
32
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
29